Medical Science Liaison - Cell Therapy (Midwest)

Medical Science Liaison - Cell Therapy (Midwest) Immix Biopharma, Inc. Greater Chicago / Hybrid Our 3 Core Values Intelligence Integrity Initiative The Medical Scientific Liaison (MSL) serves as a vital scientific partner to healthcare professionals and key experts. This role drives trusted, evidence-based engagement to support the effective communication of NXC-201 scientific data and therapeutic advancements. The MSL collaborates with cross-functional teams to facilitate product launches, medical education, and research initiatives, ensuring alignment with company strategies and compliance with regulatory standards. What You Will Do Build and maintain trusted relationships with Key Opinion Leaders (KOLs), healthcare professionals (HCPs), and key stakeholders across the hematology/oncology/cardiology/nephrology space. Engage in field activities, including scientific exchange, stakeholder engagement, and visit preparation. Develop and execute strategic KOL engagement plans, ensuring clear objectives, relevant data sharing, and scientific alignment.· Deliver timely, balanced scientific updates and respond to unsolicited medical inquiries in compliance with regulations.· Collaborate with cross-functional teams to support pre- and post-launch activities, including diagnostics and brand strategy.· Support local research initiatives, advisory boards, speaker training, and external medical education programs.· Act as the internal expert on therapeutic area trends, clinical practice insights, and competitive landscape intelligence.· Provide scientific support for formulary listings, product launches, and medical events.· Continuously enhance expertise through congress attendance, trainings Ensure full compliance and industry code of conduct, SOPs, and ethical standards in all scientific interactions. What We Look For External experience — 2–3 years of experience in Medical Affairs. Hematology/oncology/cardiology experience is strongly preferred. Scientific qualifications — MD, PharmD, or other advanced degree is preferred. Excellent communication and presentation skills. Availability for business travel. About Immix Biopharma Immix Biopharma is committed to harnessing the immune system through innovative cell therapies and other modalities to deliver widely accessible cures. Patients are waiting. Our lead asset, NXC-201, is a differentiated BCMA-directed CAR-T therapy being developed for relapsed/refractory AL amyloidosis—an area of critical unmet need. We are advancing rapidly toward potential approval and launch, with the goal of bringing a transformative therapy to patients. Immix Biopharma, Inc. (ImmixBio) (Nasdaq: IMMX) is a global leader in AL Amyloidosis. AL Amyloidosis is a devastating disease where the immune system, that’s supposed to protect, instead produces toxic light chains, clogging up the heart, kidney and liver, causing organ failure and death. Our lead candidate is sterically-optimized BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy NXC-201 with a proprietary CD3ζ, CD8 hinge and binder “digital filter” designed to filter out non-specific activation. NXC-201 teaches the immune system to recognize and eliminate the source of the toxic light chains. NXC-201 is being evaluated in the U.S. multi-center study for relapsed/refractory AL Amyloidosis NEXICART-2 (NCT06097832), with a potentially registrational design. NXC-201 has been awarded Breakthrough Therapy Designation (BTD) and Regenerative Medicine Advanced Therapy (RMAT) by the US FDA and Orphan Drug Designation (ODD) by FDA and in the EU by the EMA.